BMJ · 1977 · 244 citations · 10 references
MedicineEndocrinologyPharmacotherapyEndocrine PharmacotherapyImmunotherapyRadionuclide TherapyDiabetes MellitusGrowth HormoneGrowth Hormone TherapyHormonal TherapyPituitary DisordersResponse AssessmentBromocriptine TreatmentGrowth Hormone FunctionGrowth Hormone Replacement TherapyHormone Therapy Side EffectsImpaired Glucose ToleranceSweating DisordersSweating DysfunctionSweating Physiology
Seventy-three patients with active acromegaly were treated for three to 25 months with bromocriptine 10-60 mg/day. Seventy-one patients showed symptomatic and objective clinical improvement. This included reduction in excessive sweating, hand and foot size, and the number of headaches; improved facial appearance; and increased energy and libido. Abnormal visual fields became normal in two patients, one of whom had concomitant radiotherapy. Mean circulating growth hormone levels, obtained by averaging serial samples through the day, fell by more than 7 microng/l or became undetectable in 58 patients (79%) but did not reach normal values: only 15 patients had mean levels on treatment of 5 microng/l or less. Twenty-three patients were diabetic before treatment, and glucose tolerance became normal in 15 and improved in a further five. Provided the drug was started slowly side effects were minor when compared with the considerable clinical benefit obtained.
10
Bromocriptine treatment of acromegaly.
Michael O. Thorner, Alan Chait, Maureen M. Aitken et al. · BMJ · 1975 · 204 citations · Full text
Antonio Liuzzi, P. G. Chiodini, L Botalla et al. · The Journal of Clinical Endocrinology & Metabolism · 1974 · 122 citations
Suppression of pituitary tumor growth and function by ergot alkaloids.
Robert M. MacLeod, Joyce E. Lehmeyer · PubMed · 1973 · 108 citations